Recombinant Mouse IL-27 protein (rFc Tag)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg3374

---

Validation Data Gallery

• 

  Purity of Recombinant Mouse IL-27 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Mouse IL-27B Tyr19-Pro228 (Accession# Q35228) +linker+Mouse IL-27A Phe29-Ser234 (Accession# Q8K3I6) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 50498(IL-27B), 246779(IL-27A)
• Accession: O35228(IL-27B), Q8K3I6(IL-27A)
• PredictedSize: 77.2 kDa
• SDS-PAGE: 75-90 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

IL-27 is a heterodimeric cytokine composed of two subunits: IL-27a and IL-27b. IL-27 acts on various cell types, including T cells, B cells, macrophages, dendritic cells, natural killer (NK) cells and non-hematopoietic cells. IL-27 plays a critical role in the early regulation of T helper type 1 initiation, and enhances proliferation of naive CD4+T cells and naive B cells. It, however, also exerts anti-inflammatory functions by inhibiting the development of Th17 cells and inducing IL-10 producing type 1 regulatory T cells. IL-27 is a potentially promising cytokine for therapeutic approaches on various human diseases.

References:

1.Pflanz S. et al. (2002) Immunity. 16:779-90.
2.Villarino AV. et al. (2006) J Immunol. 176:237-47.
3.Diveu C. et al. (2009) J Immunol. 182:5748-56.
4.Hunter CA. et al. (2012) Immunity. 37:960-9.
5.Batten M. et al. (2010) J Exp Med. 207:2895-906.